## Edgar Filing: KLEIN JOSEPH III - Form 4

VI EIN IOSEDII III

Form 4												
March 04, 2										PROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMP Washington, D.C. 20549							OMMISSION	OMB Number:	3235-0287			
Check th if no lon subject t Section	ger <b>STATEN</b> 16.						AL OWN	VERSHIP OF	Expires: Estimated a burden hou			
Form 5 obligatio may con <i>See</i> Instr 1(b).	tinue. Section 17	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section										
(Print or Type	Responses)											
1. Name and Address of Reporting Person <u>*</u> KLEIN JOSEPH III			2. Issuer Name <b>and</b> Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL				-	5. Relationship of Reporting Person(s) to Issuer				
	INC [BMRN]					(Check all applicable)						
(Last) C/O BIOM PHARMAC DIGTAL D	ARIN CEUTICAL INC.	Middle)		f Earliest T Day/Year) 2009	ransaction	I		_X_ Director Officer (give t below)		Owner er (specify		
(Street) 4. If Am				nendment, Date Original Ionth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>				
NOVATO,	CA 94949							Form filed by Me Person				
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	e Secu	rities Acqu	uired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if Transaction Disposed of (D) Code (Instr. 3, 4 and 5)			) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
Common Stock	03/03/2009			Code V P	Amount 5,000	(D) A	Price \$ 10.5635 (1)		D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: KLEIN JOSEPH III - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Addre	Relationships						
		Director	10% Owner	Officer	Other		
KLEIN JOSEPH III C/O BIOMARIN PHARMACEUTI 105 DIGTAL DRIVE NOVATO, CA 94949	CAL INC.	X					
Signatures							
G. Eric Davis, Attorney-in-Fact	03/04/2009	)					
**Signature of Reporting Person	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price in Column 4 is a weighted average price. The prices actually received ranged from \$10.54 to \$10.59. The reporting person will
   (1) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.